StemCell Therapy

Having reliable mowers at the peak of the season is mandatory, which means that you and your crews have to ensure everything possible is done between jobs to keep these machines in tip-top shape.

Total Landscape Care talked with Brad Unruh, director of new product development with Hustler Turf Equipment, about his most recommended tips for enhancing mower longevity and the long term benefits of implementing them.

According to Unruh, the lifespan of a mower varies from user to user, and factors such as application, maintenance, cleaning and storage techniques can greatly affect how long they last.

Any mower, if you put it in the intended application, is going to last, says Unruh. I will say that the way we build our mowers and the way we design, manufacture, create and engineer our mowers is done to promote longevity.

When mowers are properly cared for, Unruh says hes seen some that have lasted anywhere from five to 15 years, without sacrificing cut quality or overall productivity.

To ensure youre caring for your mower properly, Unruh recommends reading through your mowers manual before using it. While its true you may be more than familiar with mowers, he says each model and brand will vary slightly, and taking time to familiarize yourself with the specifics of your machine could keep you from causing it harm later on.

Regardless of how much you spend on a mower, Unruh says its an investment nonetheless, so be sure to treat it like one. According to Unruh, the more you take care of your mower, the longer it will typically last.

To keep breakdowns from occurring, Unruh says routine cleaning and maintenance is a must, especially if your mowers are seeing a lot of action.

Before hitting the jobsite, Unruh says to check that the mowers engine is running appropriately, as well as that you are using the right type of fuel in the tank. He says to check that the batteries, belts, bearings, hoses, hydro systems and spindles are all in working order, and pay close attention to the sounds the mowers make when they are started up.

Another aspect he says is often overlooked is a mowers tire pressure, and he says to make sure they are all consistent with what your manual recommends.

Definitely follow those recommendations because when you start to get into an application, if the tire pressures are all off, it can affect your cut quality, says Unruh.

While it can be tedious, Unruh recommends taking time to clean mowers off after each use, as this allows you to get the best cut quality possible on each job and it helps you pinpoint maintenance issues before they cause downtime delays.

Since grass retains moisture, Unruh says when that grass passes underneath the mower, it can hang around and start to rust and corrode the metal. He especially recommends paying close attention to the underside of the mower deck after each mow to help keep grass from building up.

If you can keep that underside clean, that definitely helps with multiple things, not only with the care but also with the performance of the deck and keeping your blade sharp, says Unruh.

Unruh adds that dull blades are also tough on grass because they are basically carrying the grass rather than cleanly cutting it. If youve ever noticed white tips on the grass, Unruh says that means the lawn was more than likely cut with a dull blade.

If you get down and look at those grass blades, you can see ridges in the tops, and thats because of a dull blade, says Unruh. Its going to pull more, and instead of a nice clean cut, its more of a tear. Thats really tough on grass, and it definitely is not what the grass wants.

Periodically throughout the mowing season, Unruh recommends making sure you pull those blades off, deep clean them and sharpen the edges. He says you can also check with your local dealer to see if there are any other specific tips/tricks that are applicable to your specific region of the country.

Unruh says the ideal storage location for a mower is an enclosed space that will keep out the elements, as well as somewhere that wont allow moisture to collect on the machine.

Anything indoors is preferable over outdoors, he says, but in a pinch, mowers can be stored outside if they are properly and completely covered.

Unruh says if mowers are left outside and uncovered, not only will the sun wreak havoc on the mowers paint job, but serious damage can happen to rubber and plastic parts. He adds that being exposed outside also allows moisture to settle on the machine, causing rust to collect and corrosion to start. All of these things, he says, lead to the quick downgrading of the unit.

Even though its a ways away, Unruh says to keep winter storage options in the back of your mind. Depending on your location, the severity of the winter will vary, but regardless of how cold it actually gets, Unruh says to check the fuel in the tank and the batteries of your mowers.

When prepping mowers for winter storage, Unruh says to thoroughly clean the mower from top to bottom. While performing this extensive cleaning session, be sure to also check the mowers maintenance points to see if any harm has happened since the last completed job. He adds that its also important to check for any leaks before storing it.

Whether its before you put the mower away for the winter or before starting it up again in the spring, Unruh also recommends getting the mower in front of a dealer for an inspection.

Our dealers have service technicians that are experts in that machine, and they can make sure that everythings working well, that youre going to be happy and satisfied and that you dont have any problems right out the gate when you start for the for that season, says Unruh.

Excerpt from:
Increasing the longevity of your lawn mower - Total Landscape Care

2020s Vision after introducing the theme of Athlete Sustainability, we dip into the archive to see what we learn from the long career of Therese Alshammar and why Swedens head coach Ulrika Sandmarkwants to tap into the wisdom to be had from it

Back in 1991, a 13-year-old junior won the Swedish 100m backstroke title and was selected for senior international duty for the first time. CoachThomas Lovgrentold his young charge: tell them thanks but dont accept the trip youre a bit too young take things slowly, steadily and youll get there and stay there. How wise and prophetic the words of Lovgren proved to be. The teenage talent wasTherese Alshammar, on her way to becoming European champion and double Olympic silver medallist in 2000 and a world champion in 2011 with many a thrill and spill between.

It was October 2016 when Alshammar announced that she was topullthe plug on her long and illustrious racing career. There would be one more race day to go the following week. A farewell to all that, a chance to wave goodbye and to be feted by fans as her story entered swimming lore. She was 39 and she told SVT Sport: My body cannot handle the load required to perform at the level I would want to be at.

Lovgrens advice had contributed to one of the finest examples of long-term excellence in swimming history. Did Alshammar agree?

Yes, very true. I have never trained as hard as I do now. The training I do now is the hardest Ive ever done in my career. But had I done 100k a week when I was 20 or 22 then maybe I would have burned out. If you have a clever coach who gives you that advice then go with that. Its best to increase it in stages, a little at a time and save some for later.

Born in Solna in August 1977 the daughter of Britt-Marie Smedh,Olympic 100m breaststroke finalist of 1972 just over a second from a podium topped by American Cathy Carr,andKrister Alshammar, 15-year-old Therese accepted a place on the Sweden team for the first time in 1993. The result: fourth in the 100m backstroke at the European Championships in Sheffield. On retirement, she recalled:

It was one of a few fourths I got in that event for many years at Europeans. It was a nice time to be around in Swedish swimming. There were people likeAnders Holmertz(on the podium over 200m and 400m freestyle at Sheffield in 1993) andTommy Werner(second to a young Russian namedAlexander Popovin the 100m freestyle).

Alshammars history with Holmertz would rumble on down the years. In 2006, when she took three more solo wins at the 2006 Swedish short-course championships in Uppsala, her tally of 73 national titles took her one gold medal past Holmertzs high bar. By then, Alshammar was 12 years beyond her World-championships debut, 10 years beyond her Olympic debut, seven years beyond setting her first two World short-course records, six years beyond winning two silvers (50m and 100m freestyle) and a bronze (4x100m freestyle) at the Sydney 2000 Olympic Games. And, she had a year to go before she would win her first world long-course title (50m butterfly) in the same year that delivered the first world long-course record of her career (50m butterfly).

Alshammar made the World titles podium over 50m butterfly four times in 10 years. For those who scoff at the 50 in Olympic context, consider swimming history, which is stacked with the names of World record holders who never got their chance in Olympic waters because there was no 100m or no 200m in their event; because there was no 200m medley and so on and so forth. Had there been an International Swimming League in her racing years, nay decades, Alshammar would have been a tour de force.

In 2010, Therese Alshammar graced the European long-course Championship podium for an eighth time in the 50m freestyle, her victory the fourth of her career in that event at the Continental showcase. Someone in the mixed zone uttered the word retire. Flooring impertinence with a knockout smile, the star replied:

Its going so well for me, why should I retire? The 2012 Games are my goal.

That victory in Budapest was one of the top 3 career highlights she chose It was 10 years since Id won in Helsinki in 2000 and a lot of things had happened in between. It was a very nice feeling to know that you can do it all again 10 years on alongside her first national title and her first world record, over 100m freestyle in December 1999: breaking 53sec was a dream target that coach Dirk Lange and me and Sandra Voelker had been working on for some time.

Add to her treasure trove gold in the 50m and silver in the 100m butterfly at the FINA World Championships (25m) last December taking her tally of medals at the winter showcase to 17 since 1977, with 10 titles in the mix and two $100,000 pay days for World Cup series victories in 2007 and 2010, and you have swimming lore and legend. Retirement may cause us to place things in the past tense but the present tense is just as pertinent: Alshammar is aquatic vintage, her stock rises with age, her name ever household in Sweden, her status in the pool that of role model to challengers less than half her age.

It is why we find Ulrika Sandmark, Sweden head coach, turning to Alshammar in her search of the elements that contribute to Athlete Sustainability.

The Swedish Olympic Committee runs a Top and Talent program, the likes of Sarah Sjstrom and six of her national swim teammates part of the top and eligible for funding and support that is tailored to the needs to each athlete. A Talent 2022 program is aimed at the developers (it may become Talent 2023 or take on some other name given the shunting of goals and targets and plans due to COVID-19). Under the Talent 2022 scheme, the Swedish swim federation operates its own talent program, which had seven swimmers involved on the cusp on the coronavirus lockdown. Both seniors and juniors work at the elite training centre in Stockholm under the guidance of Alshammars husband Johan Wallberg, Sjostroms current coach in charge of the senior elite squad, and Sjostroms former coach, Carl Jenner, now in charge of the development program.

Therese Alshammars fledgling role is, says Sandmark:

To give talks, top pass on tips, to be around the kids and have them feed off her experience and be motivated and inspired by that to understand that the road is long. I want her to be around people because its only through that process that people open up, start to ask their questions and gain the wisdom that might help them.

USA Swimmings junior development program has similar philosophy at its heart, as described by Jack Roach in this video of part of a talk he gave to USA Junior Team members:

Become a student of the sport, he urges. Dont wait in your coach to have you do that: thats your responsibility. Junior talents racing at international level often grow up fast in terms of the resilience and self-reliance required to navigate the competitive environment. There are downside issues to that scenario, too, for another day.

Those American youngsters, of course, belong to the group of those who made it through. Some but not all will make it on to the World s leading swimming team and race in Stars and Stripes on the biggest of occasions.

Sandmark is not looking at a potential catchment of 350 million plus (in extremis, of course, the real catchment the community of folk who make it from the baby pool into the club system). Sweden has a population of 10 million and most of those wont want to become swimmers. Sandmark wants to know whats behind the 12-year hump, as captured in a slide she presented to coaches in January at the World Aquatic Development Conference (WADC) in Lund. Our artistic impression of that, to the left, shows a peak representing the number of 12 years olds in the program. As teen years kick in, the plummet to a low tide is a cliff-edge of lost talent.

There are 233 swimmers at High Schools catering for competitive sport in Sweden: just 10 of those swimmers are on the national team, Sandmark notes. Thats too few. I think it has to do with progression in all areas (of life) at that age.

Therese Alshammar is among those who Sandmark believes can make a fine contribution to understanding the issues and inspiring young swimmers to stick with it and look to the long-term.

In Lund, Sandmark reminded coaches that Alshammar has 73 international medals: no-one else in Europe has that. Shes done six Olympics and she was in the top and talent program when I was new in Sweden. Sandmark asked Alshammar for feedback based on her own experience and among answers, the sprint ace noted:

Having listed those two, Sandmark says: Im thinking a little bit about pushing the limits here. I mean when you do that your inner motivation comes up. You have to work with that and find solutions that work for you in a long career.

Therese Alshammar calculated that she had worked with 35 coaches down the years. Says Sandmark: So she always moved to different environments in order to get the best coaching.

On the back of that, Alshammars tips included:

Sandmark points to one of the slides in that part of her Lund presentation listing the feedback she received from several senior swimmers asked to help her to find answers on the subject of Athlete Sustainability.

One swimmer noted that when a coach stated to change my technique and talk over my head, I lost my motivation. There were several lessons right there, including the need to allow athletes to make mistakes, to fail and learn from that process.

Sandmark the writings of Alshammar, who has penned two books in which a four-year-old girl called Aysa learns through having fun in the water. Sandmark refers to the ending of one of Alshammars stories, This Little Child, in which a toddler talks to his mother. The head coach guesses the conversation stems from one Alshammar might have with her own young son.

Towards the end of the book, the mother asks her son: Have you made any mistakes today? Says Sandmark:

What shes doing is saying that a mistake is a part of everything. Failure/mistake: theyre part of development. Its nothing to be afraid of I think were too afraid of that.

That processes needs to be as long as it takes and will vary from athlete to athlete, person to person. Says Sandmark:

We cant forget the late bloomers. Jenny Johansson is a perfect example of that. I still can remember when she won the gold medal in Kazan (World 50m breaststroke title, 2015). I didnt believe it and she didnt believe it and no one believed it. It was so great. She started swimming when she was 10, but she did everything perfect. She was not a talent. She was a worker. Of course, she was a talent in this sense: a talent is someone who takes care of themselves, takes care of their talent. So dont forget these people, the late bloomers.

By the time Therese Alshammar was ready to move on, there was nowhere in Sweden she would not be recognised.How did that manifest itself in daily life?

In the positive sense that people say hello and ask for autographs and in that I push myself in order to be the best role model and public person that I can be while still being me, said Alshammar.

Balance and moderation are two of the life skills that Alshammar cites as keys to longevity in sport. I try to keep it balanced the being disciplined and not, she said towards the end of her career, reflecting:

My training is more balanced all round than it was in the early days. Before I could get really run down with training in the pool but still come back for more. Now I have to be more cautious and find ways not to let boredom take a hold. Youve got to keep it more interesting. I do a lot of land training, as well as swimming, which is important.

I do train harder than before but it also takes a little longer than before. I think that the great advantage with age is that you get smarter, you work things out, it becomes a question of having worked through trial and error and go with what works. So, I think for me I learned to be a lot smarter with recovery. I also have to do something I like: I actively have to seek out some alternatives to swimming.

Top pursuits: Cooking, eating, walking, surfing, talking, shopping, watching.

Travel was a necessity, too, but Alshammar embraced it. In January 2011, she was to be found on training camp in Mexico before it was off Down Under for more training and racing with her overseas teammates at the then Sydney super-squad of coachGrant Stoelwinder. At the time, she told me:

Im lucky to be able and allowed to prepare for Shanghai together with the elite squad of NSWIS (New South Wales Institute of Sport) in Sydney, where my coach Johan Wallberg and I both believe the environment plus the squad is the best in the world. The things he (Stoelwinder) sees and can put words to in swimming, together with the passion he brings to training, is unprecedented. So after training with them, race day is easy.

Them meant comeback fly aceGeoff Huegill, Matthew Abood, Andrew Lauterstein, Eamon SullivanandLibby Trickett. The latter: a rival?Alshammar painted her world with her own eyes and feel:

I dont see myself as having rivals, the biggest challenge is always chasing my own goals.

Early on that had much to do with chasing carrots: recalling that first 50m backstroke national title back in 1991, she noted:

My parents promised me I would get a red dunny jacket for winter that I really wanted if I medalled I swam for my life!

Some 20 years down the line, she said she was motivated by doing things better/harder/faster. Wallberg, she says, was the best coach in the world Cue laughter: Ive swum with enough coaches throughout the years to know. Their relationship is filled with respect and shared visions. Later: marriage and a child.

Asked how she defined success, Alshammar said:

how I measure success, thats a good question. I think it comes down to looking at what I can do better. I try to keep my approach fresh and try to do new things. Ive travelled a lot and tried different places, Ive been eager to find the best environment for me.

The money prizes that arrived in swimming during her career were a godsend, she said:

The money gives me an opportunity to be a professional, I cant think of a more fulfilling or exciting way to make a living. So yes, it has kept me in the sport of swimming. I invest most of my earnings in swimming again, in order to keep performing and progressing I believe in putting myself in good professional environments. I also try to save some for the day I feel like doing something else.

Asked how she felt about racing for titles against some less than half her age she replied:

I dont give it any thought. If anything its easier being younger because you have no experience. Experience can also be an advantage but so can inexperience, you can learn from inexperience because in youth you dont think about anything. Later on you become more self conscious and you expect too much. Thats why you get big drops and then it stops for a reason. The mind-set is what stops faster progress.

At her very beston freestyle, Alshammar looked as though she was racing through a wind tunnel, so perfectly aligned did she raced, so fine her angle of buoyancy, the spray of her sprint flying off her fingertips as she sped along.o do what I wanted to do for swimming.

In Rio at the 2016 Olympic Games, her sixth Games, Alshammar made the semis of the 50m freestyle. It would be her last race for Sweden. She left her last race for a moment of her choosing: October 2016 saw her fly down a pool one last time as an elite athlete in Stockholm.

At the time, she spoke of what Sandmark had been so happy to hear in a 39-year-old: her love of swimming, one that means she will not regard her status in the past tense, rather, she will be a swimmer for life:

Swimming is fantastic as a form of exercise and I hope I will always apply it. After [the last race next week] I will not have the same strict focus and have no intention to qualify for the [Sweden team for international duty]. Ill swim for the fun of it and to feel good, not to push my body to the max.

Wallberg took up the head coach job full time at the Stockholm excellence centre in January 2017, as Jenner moved to head the development program after celebrating Sjstrom becoming the first Swedish woman to claim Olympic gold in the pool. Alshammar imagined she would have a role to play too, saying in October 2016:

It is something that comes naturally our son is already swimming and its great to train him and other young people.

Alshammar first made an international podium for Sweden in at the 1997 European Championships in Seville. It was 14 years later, in 2011, that we saw her put a twist in the tale of Piaf when she said that while there were many things on her list of things that she could have done differently down the length of her long international senior race career, she would actually change nothing. She said:

I would change so many things that you wont have space [to publish them]. I dont think I would change anything if I could because everything I did has made me into the person I am today. If youre willing, you can learn from your biggest mistakes, so it has been a journey and it has been fun.

There had been highs and lows but since accepting her first selection for Sweden, Alshammar had never wavered in her love of the sport:

I never thought of walking away I have done other things, I have trained less and focused more on other parts of my life than the swimming part, but I never really thought Ive had enough.

Knocked by injury in 2012, Alshammar started her Olympic career at Atlanta 1996 and ended it 20 years later at Rio 2016. In the late 1990s, she had Diva tattoed on her lower back to remind her to work hard. Looking back in 2011, she told me:

When I was a bit younger I was a bit of a diva, because I didnt train so hard and didnt put in the effort. I made the tattoo to remind me that my previous ways werent so efficient and successful, and also as a tribute to women.

Day 8 finals, Oriental Sports Center, Shanghai 2011 World Championships, Womens 50m freestyle (contemporary notes)

Therese Alshammar, 26 days shy of her 34th birthday, became the oldest world swimming champion in the history of womens swimming with a 24.14sec display of technical brilliance build over years of honing and correcting on a trajectory to that elusive place that the Swedish sprinter says does not exist: perfection.

Off her blocks and into her stroke in one fluid movement, Alshammar returned to that place of technical superiority she had known more than a decade ago on her way to two silver medals at Sydney 2000: it looked like she was swimming in a wind tunnel of the kind you see in car tests, turbulence-free streamlining the aim.

And look where that took her to: the 24.13 world record of Inge de Bruijn (NED) at Sydney 2000, when Alshammar was closest to the born-again Dutch diva, remains the best textile-suit time there ever was, though De Bruijn wore a bodysuit. Alshammar is the best there has ever been in the cut of suit now allowed under rules that have breathed new life into a sport that was drowning in shiny suits just two years ago.

Where Alshammar has struggled to hold back the pack in the closing metres in the past, today she held on, taking revenge on the Orange nemesis of her career, the silver going to Ranomi Kromowidjojo (NED), 24.27, and Dutch teammate and comeback mum Marleen Veldhuis, on 24.49. That confined Britains Fran Halsall, on 24.60, to the worst of places, fourth, for the second time this week.

All to the good if you want to be hungry for a home Olympic Games. Great news for Alshammar too. Where she had a world title in the past in a non-Olympic event, 50m butterfly, she now has one in an Olympic event.

Asked about the oldest title Alshammar smiled and said that she saw it as neither positive nor negative: Its just a fact.

The result:1. Theresa Alshammar, Sweden, 24.14;2. Ranomi Kromowidjojo, Netherlands, 24.27;3 Marleen Veldhuis, Netherlands, 24.49; 4. Francesca Halshall, Britain, 24.60.

Motherhood But Not Ready To Move On

In 2014, Alshammar spoke to this author in the early days of comeback after the birth of her first child. Task No1, she said: shedding the 20kg of weight she had gained while getting little Fred ready for the world.Asked if she had to work harder to get back and maintain form, Alshammar replies:

Not necessarily more time but you have to use more imagination, you have to be more creative in how you keep your body at peak performance. One of my beliefs is that you have to change something each season to keep it at its optimum peak powers.Both mentally to keep you sharp and interested in exercise in general and also if you do the same things over and over you wont be as explosive or as interested in doing those things perfectly with the right choreography and trying to get things at a perfect movement. I think that is one of the keys to my long career.

Alshammar continued to train in water and gym until four days before Freds arrival. Three months after giving birth, she made her way back to a regime that was based on steady steps and patience. It took six months before the sprinter felt as though I had my strength back. I think that is just your body healing and getting back to where it was.

Training became a family affair: all three would go to the pool for 8am for the first water session, then the gym, then home and back to the pool later in the day. Life will be similar from now on, though Alshammar wont be getting as wet quite so often.

History repeats. Alshammars mother, Britt-Marie Smedh raced in the 1972 Olympic 100m breaststroke final and later passed on valuable tips to her daughter. Said Therese:

She taught me how to swim and was my first coach when I was five or six.With swimming you start early and you have morning practice so family is very important that they engage in your sport and give you support. Not just encouragement but actual physical support, they need to drive you to practice in the morning, my mother has been a very big influence. That has been a very important factor that you have trust and support from family.

In our next look at Athlete Sustainability, well consider the things that make swimming unsustainable and unattractive for many youngsters and the families asked to support a pathway that comes with no guarantees but a huge commitment.

Share and Tweet This Story

Read this article:
Tips On Athlete Sustainability From Therese Alshammar - Swedish Sprint Ace & Model Of Swimming Longevity - Swimming World Magazine

It is important to understand that longevity can only be achieved through a lifelong commitment to exercise and eating a healthy, balanced diet.

Neglecting one aspect will offset the gains in the other so it is vital to heed this general precept.

What research can offer you however is the specific decisions that reduce your risk of death from all causes, making them an essential addition to your overall approach.

To that end, one promising strategy is to drink chamomile tea, which is made from an infusion of the daisy-like flowers of the Asteraceae plant family.

READ MORE:High blood pressure: The popular Asian ingredient proven to lower your reading

Fourteen percent of the people in the study drank chamomile tea.

The data showed that consuming chamomile was associated with a 29 percent decreased risk of death from all causes among women compared with nonusers, even after adjusting for demographics, health conditions and health behaviours - this effect was not present in men, however.

"The reason for a difference in our reported findings between Hispanic women and men is not clear, although women were shown to be more frequent users of chamomile than men," said Bret Howrey, assistant professor in the UTMB department of family medicine.

He added: "This difference may be due to traditional gender roles whereby women manage the day-to-day activities of the household, including family health, and may also reflect greater reliance on folk remedies such as herbs."

he antioxidants found in chamomile tea have also been linked with a lower incidence of certain types of cancer.

Chamomile contains the antioxidant apigenin.

In test-tube studies, apigenin has been shown to fight cancer cells, especially those of the breast, digestive tract, skin, prostate and uterus.

Additionally, one study of 537 people observed that those who drank chamomile tea two to six times per week were significantly less likely to develop thyroid cancer than those who did not drink chamomile tea.

Read the original here:
How to live longer: The hot drink proven to reduce risk of early death from all causes - Express

Replacing professional batteries can be a significant cost center for healthcare providers and organizations, given the proliferation of increasingly portable and smaller medical devices that are used for a range of applications. Battery safety is also of paramount importance in the healthcare world and the selection of the appropriate batteries for specific devices will help ensure longevity while keeping costs manageable.

Jane Lo, Senior Director, Duracell B2B Asia, shares some tips and advice on how healthcare providers can reap the benefits of using medical device batteries that are rigorously tested and proven to meet the demands and safety standards such as ANSI and IEC.

What are some key considerations/concerns for healthcare providers when it comes to batteries for medical devices and their related applications?

While the operation of medical devices are powered by battery, its quality and reliability are undeniably important. Procell Alkaline batteries are manufactured using superior cell design* ensuring our highest quality cell construction. Batteries are tested in order to guarantee highest quality and reliable performance. Environmental testing is also conducted to insure dependable and consistent use.

What are the common types of batteries used in medical devices and what are the typical ranges of their shelf lives/life cycles?

They are alkaline, high power lithium and lithium coin. The typical ranges of the devices are based on the manufacturer specifications. However, by appropriately choosing either Procell Alkaline Intense Power or Procell Alkaline for your device, you could maximize the longevity of the battery, and may minimize battery replacements, vs. prior Procell Alkaline AA, AAA, C, and D batteries.

What are some battery safety standards that users and healthcare providers should be aware of?

Battery for medical devices must comply with the International Electrotechnical Commission (IEC) standard. In Procell, we design, safety, manufacturing, and qualification follow our stringent battery standards, which incorporate parts of the American National Standards Institute (ANSI) and IEC battery standards.

With medical devices getting smaller and becoming increasingly common in applications such as remote or tele-monitoring of patients, what trends or future developments do you see in battery technologies in the near future?

We believe lithium coin will be the new trend for medical devices in the coming future. Featuring high energy density (3V) with a flat and low self-discharge, Procell provides 2016, 2025 and 2032 sizes lithium coins for professional medical devices.

How can healthcare providers keep up to speed in terms of battery safety and management while keeping maintenance costs sustainable?

Procell understands how critical it is for professional end-users to drive the profitability of their businesses. When it comes to batteries, this is achieved through minimizing costly battery replacements.

By conducting intensive device testing in our labs and real-world experience with OEM partners, Procell has discovered that the way to dramatically extend alkaline battery life and cut replacement costs is to engineer device-specific industrial alkaline batteries with unique power profiles.

Procell is the only brand to offer device-specific professional alkaline batteries.

On top of our Procell Alkaline battery redesigned for longer lasting* and consistent performance in general-purpose devices, we also offer Procell Alkaline Intense Power batteries, a new battery range specifically designed with a unique power profile to last longer* in high drain professional devices.

By appropriately choosing either Procell Alkaline Intense Power or Procell Alkaline for your device, you could maximize the longevity of the battery, and may minimize battery replacements, vs. prior Procell Alkaline AA, AAA, C, and D batteries.

(*vs. prior Procell Alkaline AA, AAA, C and D batteries)

Learn more about Procells range of professional batteries here.

View original post here:
Maximizing the lifespan of medical devices through the appropriate power source - Healthcare IT News

Ill start by saying this: masks are important right now. For the immediate future we need to get people on board about taking our actions seriously in a different manner. Our way of living has changed and working with each other is for the betterment of humanity. That is to say, if we all love life then we need to work together.

Ill continue by saying this: humans were not meant to live in masks for the rest of our existence. We must live IN the world, not hide from it behind band-aids. Masks do not cure, prevent, or keep us safe from any future (or present) diseases that the world throws at us. They are a temporary measure that have fast become a sticky subject within our culture.

This is the ideal time in history to look at our personal health more thoughtfully. Americans have gorged themselves on cheap, fried, nitrate-ridden, gluttonous diets for decades now. Many of us think mowing the yard is a good days exercise or that drinking a glass of water for every soda is a healthy ratio. Our way of life, as it might be tolerable, does not allow us to thrive. It barely allows us to survive.

The environment we live in is much more toxic than it was even 50 years ago. The quality of what we ingest, be it air, food, drink, visually or even socially is degrading by the year. Our bodies are continually working harder to keep us from growing old. Diseases such as diabetes, cancer or even a heart condition may be attributed to how we live our lives.

We must continue to evolve how we exist on our planet and the thing that each of us can do going forward is to take our health into our own hands.

Things such as hormone balance, foods that boost our immunity, correct exercise for longevity, and meaningful mental health practices are all things that are much more productive in preventing sickness. In addition, they add years or even decades to the quality of life for humans. Ive studied these benefits over the past 12 years and was sold on the win-win of longevity and health when I started to see the benefits in my own life.

There is not a magic bullet, but there is a lot of pertinent information out there. With the level of unknown at this point in 2020 it is only prudent to do what we can personally to help ourselves.

Consider going to drjboss.com to start your information gathering and to begin to think differently about our current situation in 2020. There are also great places here in Emporia such as Natures Paradise Health Food Store that have great personal advice on rebooting the body towards longevity. Biohacking is the next trend and newest weapon for the human race to combat our anxieties in the world.

Fighting, ridicule and fear are not going to help us get back on track, but certainly health measures are a step in the right direction.

Wouldnt it be great to not wear masks? When coronavirus has subsided, who is to say that tequila virus wont be next? Or trench foot? The world is full of vaccines that are less than 50 percent effective. Personal health is under your control and gives you a better place in the world for a brighter life and a safer future.

To mask or not to mask? That is one of the main questions in society right now. But the answer is not in the mask; the solution is within us.

Cory Bosiljevac

Marketing Executive

See the article here:
Beyond the Mask | Free - Emporia Gazette

Nicole Junkermann

Nicole Junkermann is an international entrepreneur and investor, and the founder of NJF Holdings, an international investment company with interests in venture capital, private equity, and real estate. Through NJFs venture capital arm, NJF Capital, Nicole oversees a portfolio of over 30 start-ups across three continents, including in healthcare, FinTech, and deep tech.

I was a very early investor in both healthcare and biotech, particularly focusing on early-stage companies looking to utilise the latest advancements in technology to make much-needed breakthroughs in their fields. My focus when I first invested in this area was to support the companies on a mission to help people live longer and healthier lives; and this remains my focus today.

In the UK, the All-Party Parliamentary Group for Longevity recently published The Health of the Nation A strategy for healthier stronger life in February this year. This report found that the UK must prepare for a very large increase in the number of cases of people in poor health over the next 15 years, especially in the older population. For example, in England, it is predicted that by 2035, 70% of people aged 55 and over are expected to be affected by obesity-related illnesses.

In the report, the UKs Chief Medical Officer, Professor Chris Witty now a household name in the country as he helps lead the UK governments strategy to tackle the COVID-19 pandemic highlights the importance of controlling four behaviours to reverse the trend of declining health in old age: smoking, unhealthy eating, alcohol consumption, and physical inactivity. According to Witty, by tackling these four factors we could prevent up to 75% of new cases of heart disease, stroke, type 2 diabetes and 40% of the incidence of cancer, and potentially many cases of dementia.

However, many healthcare professionals are also turning to technology to offer solutions to improve longevity by tackling age-related medical illness. This is a relatively new field within healthcare technology, and I am pleased to have moved quickly to invest in two promising early-stage US-based companies both tackling age-related illnesses as a way of improving peoples longevity.

Introducing Gordian Biotech

Gordian Biotech is a great example of how companies are turning to the latest technology advancements particularly in Artificial Intelligence (AI) and machine learning to help in the fight to prevent age-related illnesses.

The San Francisco-based company is on a mission to pioneer a novel discovery platform to radically improve drug development for complex diseases of aging. The company is redefining the latest screening method for age-related conditions by using the latest AI and machine learning technologies to process and analyse vast data sets and integrate the analysis with the latest in biological research.

Introducing Cambrian Biopharma

One of my more recent investments is Cambrian BioPharma, a clinical-stage biopharmaceutical company founded in 2019 and focused on developing therapies to prevent and cure age-related diseases with the help of AI.

Cambrian is based in New York City with operations across the US and Europe, and is focused on the basic biology of aging, a field known as geroscience. I am delighted to be part of Cambrians development journey, and although still very early days, I look forward to hopefully seeing them successfully developing the therapies which will have a real benefit when tackling age-related diseases.

These two companies are great examples of the types of opportunities investors will be looking to as investment in healthcare start-ups continue to grow; ie companies who manage to effectively combine cutting-edge technology with leading scientific research. Im looking forward to seeing this sector develop further in the coming months and years.

Go here to read the rest:
Nicole Junkermann on health and life longevity | Business Leader News - Business Leader

Self-massage is a wonderful tool to use if you need to release a bunch of muscle tension. Were living in a very stressed and tense world right now and its important to learn how to self-soothe. If you cant get to a massage therapist at the moment due to financial problems or Coronavirus. Then, learning to knead those tight knots out on your own, or with your partner will help you big time. We could all use a helping hand right now and we thought we could help you relax those tense muscles with these tips.

It might seem like human toughness is a luxury at the moment. With social distancing rules strictly in place, were not allowed to do much touching at all. This can take its toll on us all, in more ways than you might think. Self-massage is a really powerful tool to help get you through even the most stressful of times. Of course, self-massage is not as nice as having a professional do it for you, but you might enjoy the connection and time you spend taking care of yourself. These are tough times and we need to nurture ourselves and practice self-care more than ever before.

Interestingly, the human touch is not just something we enjoy sometimes. Its a biological necessity and we need it to survive. Touch is the very first sense we develop as babies. If an infant is starved of touch it will fail to meet growth standards. Therefore, we are trying to tell you just HOW powerful a tool it is.

According to massage experts, touch builds cooperative relationships and improves immunity. So any form of touch can help increase pleasure hormones and reduce stress hormones. However, self-massage is an especially effective tool particularly during times when you have to be alone or cautious about touching one another. But knowing exactly how to self-massage will be most effective. Moreover, it can relieve muscle tension created by physical and emotional stress, which will improve the health of our bodies and minds.

Finding ways to progressively relieve muscle tension is a life-changer you cant miss out on. We cannot emphasize enough how important it is for your health to manage your stress and anxiety. If youve been experiencing intense backaches, neck pain, or shoulder tightness, youre most probably suffering from anxiety or stress. You see, when youre really anxious or stressed in your life, it can manifest physically as a direct symptom. The body automatically responds to this with muscle tension. However, self-massage can be done in a variety of different ways, youve just got to learn what works best for you.

Experts also recommend progressive muscle relaxation as a method that helps relieve intense muscle pain. They explain that progressive muscle relaxation is where you tense a group of muscles as you breathe in, and you relax them as you breathe out. You work on your muscle groups in a certain order. The trick is to relax your body fully because it will then no longer feel anxious. But you need to practice this regularly for a few weeks to get better at this skill. With some time, you should be able to self-massage and relieve some stress and tension on your own.

In the beginning, you might find it easier to follow some self-massage tutorial videos on YouTube or an audio recording. You need to learn all the major muscle groups. When searching, have a look for progressive muscle relaxation audio recordings. Self-massage is also a good way to help you remedy poor sleeping patterns at night.

There are usually many reasons why we have giant knots in our backs or necks. However, for many people it is often a combination between too much stress and poor posture. Very few of us have perfect posture. Whether you sit or stand during the day. In fact, those of you who work on your feet often stand swaybacked.

This is why self-massage and knowledge are really going to make a big difference. Then those of us who work at desks push our heads forward and hunch our shoulders. We then sit so long that our hips become tight. And over time, our muscles get stuck in the memory of those positions.

However, as we mentioned its not only your posture creating these knots. Your muscles remember emotions almost too well. It is a natural reaction for our muscles to contract when we stress to protect us from harm. But then when the threat disappears, our muscles let go. Chronic stress is when the muscles can never relax. And without self-massage, prolonged chronic stress leads beyond discomfort to physical and mental disorders.

Experts explain that a muscle knot is a trigger point. Moreover, its a contraction within a muscle that refuses to release. Sometimes the pain is localized to one area or it can radiate to other parts of the body. For example, a trigger point in a neck muscle you dont feel may be responsible for the pain in your jaw you do feel. The good news is that, through self-massage, we can release trigger points before our bodies start compensating elsewhere.

Often we think we cant get a massage in when nobody is willing to do it for us. Or many, your partner isnt near or maybe you dont have one right now. Thats okay because self-massage will take care of it for you. You can press on or roll your trigger points with your fingers, knuckles, or a tennis or massage ball. Its a little bit of work for yourself, but trust us when we say, its totally worth the effort.

Just try not to spend more than five seconds on one spot, because this cuts off blood flow and prevents healing.

Lets define one muscle at a time.

Most of us experience some kind of neck pain on our journeys. Self-massage is a fantastic way to help relieve this tension whenever you need it.

Do you experience chronic headaches? Experts recommend examining your sternocleidomastoids, the ropy neck muscles that extend from just behind the ear to the collarbone. Apparently, looking down at a keyboard or screen creates trigger points on the muscle which then refers pain into the forehead, ears, or cheeks.

To self-massage, gently pinch the muscle between your thumb and forefinger and roll it like a piece of taffy. Work your way up the entire rope.

This part of you can get completely locked up, tense and painful. After a while, it results in a that travels from the neck into your shoulders. These are called your levator scapulae, or shoulder-shrugger muscles.

If you need to self-massage these, then wrap an arm around yourself to touch the top inside corner of your opposite shoulder blade. Press on the knots and roll back and forth with your fingers. Or place a ball between your shoulder and a wall to dig deep into these trigger points.

A lot of emotions are held within our chest region, as this is where the heart chakra lies. Therefore, its very important to love and not neglect this part of our bodies.

In fact, when your body is seated with rounded shoulders for long periods of time, the pectoralis major muscles collapse and grow tight. This can potentially cause shortness of breath or pain in the front of the shoulder and down the inside of the arm.

To self-massage these muscles, run your fingers or knuckles just below your collarbone from the center outward. Try to move away from the space where you feel a pulse. Or, while standing, pin a ball between your chest and the wall with your arm outstretched to roll out this area.

Now we know this part of our bodies can get really sore. You need to self-massage this area gently.

If youre standing at a counter or at a desk without your core engaged, you may feel pain in your lower back or buttocks. The source could be a trigger point in your quadratus lumborum, two muscles that sit on either side of your spine between your pelvis and your lowest rib.

Try to self-massage by lying on the floor with your knees bent. Secure the ball on your lower back and gently roll over tender spots.

We hold a significant amount of muscle tension and soreness in our buttocks.

Often the pain in your lower back is emanating from trigger points in your buttocks. To get into the meaty gluteus maximus muscles, sit on a ball and roll in all directions.

Try to self-massage by leaning back to roll just below the hip bone. For more pressure, prop the foot to the side you are rolling out on the opposite knee (figure four position).

If you allow your body to stress and hold too much tension in the calves, then you will cause the muscles in your feet to knot up. Its important you take time to self-massage by pressing your fingersinto the arch of your foot.

You can also self-massage by rolling on a golf ball youve chilled in the freezer. If left untreated, these knots can lead to a type of tendinitis in the foot called plantar fasciitis.

We store a lot of emotional stress in our feet too, which is why going barefoot on some grass or in your garden really helps us ground and relax. Give it a try.

And if youre fortunate enough to have a partner then communicate with them. Learn to give each other massages, because its not always ideal to self-massage. Besides, its good to help relax one another. Giving a massage isnt just a nice thing to do; it can also decrease anxiety for the giver.

If you are going to give each other a massage then make sure you get feedback from your partner or housemate. You dont want to be too aggressive or too gentle. Start by asking, Do you want more pressure or less? Massage experts recommend using broad strokes with the palm of your hand and moving in one direction. But ideally, you want to move toward the heart. Its also a plus to add a drop of lotion or oil to your hands to improve glide.

Gritty strength is probably the one most important character traits we need to develop right now. 2020 has by far been one of the most trying and challenging years of them all. Find out how to focus on developing grit.

Knead those knots away. Washington Post. https://www.washingtonpost.com/graphics/2020/lifestyle/wellness/how-to-give-a-massage/

Stress Management: Doing Progressive Muscle Relaxation. Michigan Medicine. https://www.uofmhealth.org/health-library/uz2225

Originally posted here:
How To Self-Massage To Relieve Muscle Tension And Stress - Longevity LIVE

Producing director (PD) Choi Bo Pil of Running Man spoke about the programsupcomingbig milestone!

Running Man premiered on July 11, 2010 and the beloved variety show will soon be celebrating its 10th anniversary. While the cast and crew cant put on a big party with fans because of COVID-19 precautions, theyre preparing some events to mark the special occasion, such as a live broadcast in next weeks episode.

Choi Bo Pil became the main PD of Running Man in March after being assistant director, and he recently sat down for an interview with News1 to share his thoughts on the anniversary.

As a Running Man fan myself, Im sincerely celebrating the shows 10th anniversary, he said. I worked on the program asan assistant director for a few years but it hasnt been long since I became the director, so I feel a bit embarrassed to be talking about the glory of the 10th anniversary. I hope that the members, staff, and viewers who have brought the show to its 10th anniversary will look on it with pride. From what I know, its the only variety show other than Infinite Challenge to make it to its 10th anniversary, and all of the production team feel the weight of that so were working on it while feeling a sense of responsibility.

Choi Bo Pil says he thinks the reason for the shows longevity has been the casts chemistry. The big asset thats unique to Running Man is the members shared memories, relationship, and friendship, which had been built up over 10 years and cant be imitated by other variety shows. Their chemistry makes people feel happy just seeing them together, no matter what combination theyre in. Im always thinking about how we can improve on the way we conveytheirenergy to the viewers.

Choi Bo Pil was asked to describe why the show is also so popular outside of Korea. He attributed this to the way that the cast and the PDs before him have made it so that viewers can understand the characters easily through the situations alone, making it possible for everyone to laugh along. When I see how the characters theyve developed and the fandom have continued like this all the way until today, I simply feel so grateful for the efforts of the members and producers at the time, he said.

News1 also asked Choi Bo Pil to talk about any difficultaspectsof helming the show.

As a director, I feel very lucky to take on Running Man,' he replied. Im able to try more new challenges because of these characters that have been created over a long history and the support of regular viewers. However, paradoxically there are also times when the history stands in the way. Sometimes an idea weve come up with in a meeting turns out to be something already done in the past or gives a sense of dj vu. So theres a pressure to make sure that what we do is different from the missions and games done over the past 10 years while feeling new at the same time. Also, were really limited when it comes to locations recently because of the COVID-19 situation. This is my biggest concern lately.

Choi Bo Pil then spoke about how theyd had several plans for the 10th anniversary but many things arent possible right now. However, we want to create a meaningful memory, so weve planned a 10th anniversary celebration that viewers can take part in, he continued. The viewers wont just be watching; were planning a race where theyll be directly influencing the result. Im a bit worried because I dont have a lot of experience in this sort of thing, but I think its worth giving it a shot because we have the best cast members.

Lastly, Choi Bo Pil said a message to viewers. Thank you so much to the viewers who have loved Running Man for the past 10 years, he commented. Its an amazing thing for a variety program to last for 10 years. I sincerely thank you for making it so that the Running Man brand could continue all this time and not lose its value. I want to express my thanks and say Youve worked hard to the senior PDs who have maintained this long history, the production team, and the members who have taken charge of everyones Sunday evening without any issues for 10 years.

Watch Running Man below!

Watch Now

Source (1)

How does this article make you feel?

Read the rest here:
Running Man PD Talks About 10th Anniversary, The Secret To The Show's Longevity, And More - soompi

Market Study Report LLC adds a new report on Longevity Biotech Industry Market Share for 2020-2025. This report provides a succinct analysis of the market size, revenue forecast, and the regional landscape of this industry. The report also highlights the major challenges and current growth strategies adopted by the prominent companies that are a part of the dynamic competitive spectrum of this business sphere.

The Longevity Biotech Industry market report is an in-depth analysis of this business space. The major trends that defines the Longevity Biotech Industry market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Request a sample Report of Longevity Biotech Industry Market at:https://www.marketstudyreport.com/request-a-sample/2768739?utm_source=Algosonline.com&utm_medium=AN

COVID-19, the disease it causes, surfaced in late 2020, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Other information included in the Longevity Biotech Industry market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Revealing a gist of the competitive landscape of Longevity Biotech Industry market:

Ask for Discount on Longevity Biotech Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2768739?utm_source=Algosonline.com&utm_medium=AN

An outlook of the Longevity Biotech Industry market regional scope:

Additional takeaways from the Longevity Biotech Industry market report:

This report considers the below mentioned key questions:

Q.1. What are some of the most favorable, high-growth prospects for the global Longevity Biotech Industry market?

Q.2. Which products segments will grow at a faster rate throughout the forecast period and why?

Q.3. Which geography will grow at a faster rate and why?

Q.4. What are the major factors impacting market prospects? What are the driving factors, restraints, and challenges in this Longevity Biotech Industry market?

Q.5. What are the challenges and competitive threats to the market?

Q.6. What are the evolving trends in this Longevity Biotech Industry market and reasons behind their emergence?

Q.7. What are some of the changing customer demands in the Longevity Biotech Industry Industry market?

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-longevity-biotech-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Spider Vein Removal Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-spider-vein-removal-treatment-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Liver Diseases Therapeutics Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-liver-diseases-therapeutics-drugs-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Report : https://www.marketwatch.com/press-release/edible-flakes-market-trends--industry-analysis-share-growth-product-top-key-players-and-forecast-2025-2020-07-08?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Visit link:
Longevity Biotech Industry Market Analysis with Key Players, Applications, Trends and Forecasts to 2025 - AlgosOnline

Wine has always been one of our planets great social connectors, as well as a symbol of generosity, pleasure, and celebration.

This spring, however, while the COVID-19 pandemic has reminded us how important human connection is, and the global Black Lives Matter protests have shown how far we have to go in creating a more equitable society, theres renewed energy toward making the wine world more inclusive.

Although there are more than 8,000 wineries in the United States, about one-tenth of 1% of the winemakers and brand owners are Black, estimates Phil Long, president of the Association of African-American Vintners and owner of the Longevity winery in the California Bay Areas Livermore Valley.

Which is why, Long says, the real goal of our organization is promoting awareness letting people know we exist, and we make great wine.

Its true. Many of the wines are absolutely delicious, and range from big, bold reds with savory flavors to refreshing whites, as well as unusual, experimental sparkling wines made from hybrid grapes.

I didnt know winemaking was a career choice, says Long, who has a degree in architecture and spent years as a creative director in the Bay Area. For Italian-Americans, wine is part of their culture and heritage. Most Black winemakers dont have that.

Getting attention hasnt been so easy. The only Black-owned labels that most people are aware of are celebrity brands such as singer-songwriter John Legends LVE collection, made by Napas Raymond Winery, and NBA star Dwyane Wades D. Wade Cellars, made by Napas Pahlmeyer.

Theodora Lee, owner of Theopolis winery in Mendocino, California, is starting to see some change, though. While acknowledging that the injustices and killings of Black men by the police are driving the Black Lives Matter protests, Lee says the movement has helped spotlight Black wines, causing a surge in sales.

Lee, a shareholder, partner, and trial lawyer at Littler Mendelson, says sales have doubled from January to June, and shes signed up many more wine club numbers.

Lee grew up in Texas as the daughter of educators. She learned to love wine via visits to law firm mentors in Napa, California, and thought: I could be a grape farmer and still keep my job. She took viticulture courses at University of California at Davis, hired soil experts to help her decide what grapes to plant, and ended up with five acres of petite sirah in Mendocino County. In 2006, she sold her first harvest and six years later started bottling her own wine.

COVID-19, she says, has encouraged direct-to-consumer sales, which has also helped support Black business owners. Shed like to see bigger wineries partner with Black wineries to help them with distribution.

Thats what happened to the AAVs Long, who launched a national distribution deal with giant Bronco Wine Co. for his two entry-level wines just before the coronavirus hit. After the Black Lives Matter protests, he saw more online sales in the first two weeks of June than in all of 2019. The question, he says, is how we keep that going.

In South Africa, the path to becoming a Black winemaker hasnt been easy either, despite empowerment efforts. The country now has about 60 Black-owned brands, according to Wines of South Africa. Ten are imported into the U.S.

Ntsiki Byela, the countrys first Black female winemaker, says, Wine is not part of our history. A collaboration with Napas Helen Keplinger, set up by Mika Bulmash of U.S. importer Wine for the World, gave her the funds to start her own winery, Aslina.

Its great that people are publishing lists of Black winemakers, says Krista Scruggs, owner of Zafa Wines, based in Burlington, Vermont. But we need to go way beyond that. She is pushing boundaries by making cider and wine blends and using hybrid grapes to make natural sparkling wines.

Julia Coney, a Black wine and travel writer in Washington, explains, One of the problems is that most wine is not marketed to people who look like us. We have to change the perception of what a wine drinker looks like.

Coney just launched Black Wine Professionals to help address the diversity problem in the wine industry. Meanwhile, AAAV sponsors scholarships to encourage others to work in wine and nonprofit organization Wine Empowered is offering tuition-free wine classes to women and minorities in the hospitality industry.

Read the original here:
Less than 1% of US winemakers are Black, but efforts being made toward inclusion - yoursun.com

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Continued here:
Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Jewish Life News

INQOVI is the first and only orally administered hypomethylating agent for the treatment for adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML),1 two blood malignancies.

Approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. The ASCERTAIN phase 3 study evaluated the five-day, decitabine exposure equivalence between oral INQOVI and intravenous decitabine. The safety and efficacy of INQOVI was also assessed in the clinical studies.

The review and approval of INQOVI was conducted under the ORBIS initiative from the FDA Oncology Center of Excellence (OCE) with simultaneous submission and regulatory review in the U.S., Canada, and Australia. The FDA also reviewed the NDA under Priority Review status. INQOVI is not currently approved in Australia. INQOVI was formerly named ASTX727, its experimental compound code.

Intravenous or subcutaneous administered hypomethylating agents have been the cornerstone for the treatment of patients with MDS and CMML since the mid-2000s, said Guillermo Garcia-Manero, MD, Professor and Chief of Section of Myelodysplastic Syndromes, Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas, and Principal Investigator of the ASCERTAIN clinical study. The FDAs approval of INQOVI builds on the proven therapeutic utility of hypomethylating agents in these diseases and offers a new orally administered option that offers patients an alternative to five consecutive days of IV infusions every month during a treatment period that can extend to several months.

Until now, patients with intermediate and high-risk MDS and CMML have not had an approved, orally administered hypomethylating agent option for treatment of their disease, said Mohammad Azab, MD, president and chief medical officer of Astex Pharmaceuticals, Inc. The INQOVI clinical program was designed to deliver an oral alternative to IV decitabine based on comparative decitabine exposure data in the clinical trials, and to assess INQOVIs safety and efficacy profile. As part of the ORBIS project initiative of FDA and Health Canada we were able to share and address information requests simultaneously with both agencies resulting in a more efficient review and completion of assessment in a timely manner. The outcome is expedited availability of this important oral alternative to patients in both countries, added Dr. Azab. We greatly appreciate the FDAs priority review and Health Canadas review of the INQOVI NDA / NDS under Project ORBIS and the approval of a new therapeutic option for patients with these diseases.

INQOVI is an orally administered, fixed-dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine,2 an inhibitor of cytidine deaminase.3 By inhibiting cytidine deaminase in the gut and the liver, INQOVI is designed to allow for oral delivery of decitabine over five days in a given cycle to achieve comparable systemic exposure to IV decitabine (geometric mean ratio of the 5-day cumulative decitabine area-under-the-curve following 5 consecutive once daily doses of INQOVI compared to that of intravenous decitabine was 99% (90% CI: 93, 106).1 The phase 1 and phase 2 clinical study results have been published in Lancet Haematology4 and Blood,5 respectively. The phase 3 ASCERTAIN study data was presented at the American Society of Hematology (ASH) Meeting in Orlando, Florida, in December 2019 by Dr. Garcia-Manero.6

Astexs parent company, Otsuka Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. previously announced that, subject to regulatory approvals, commercialization of oral INQOVI in the U.S. and Canada will be conducted by Taiho Oncology, Inc. and Taiho Pharma Canada, Inc. respectively.

Our partnership with Astex is a demonstration of the commitment that Taiho Oncology has to bringing new therapeutic options to patients with cancer, said Tim Whitten, president and chief executive officer of Taiho Oncology, Inc. The approval of INQOVI makes the possibility of at-home hypomethylating agent treatment of intermediate and high-risk MDS and CMML a reality, enabling patients to take their medication from the convenience and comfort of their home. This is especially significant during the COVID-19 pandemic, allowing patients to potentially reduce the number of office visits needed for current IV treatment administration. We look forward to working with all healthcare professionals to help deliver the first new oral HMA treatment alternative for patients with intermediate and high-risk MDS and CMML in nearly fifteen years.

About INQOVI (See https://www.inqovi.com)

INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.1

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Myelosuppression: Fatal and serious myelosuppression can occur with INQOVI. Based on laboratory values, new or worsening thrombocytopenia occurred in 82% of patients, with Grade 3 or 4 occurring in 76%. Neutropenia occurred in 73% of patients, with Grade 3 or 4 occurring in 71%. Anemia occurred in 71% of patients, with Grade 3 or 4 occurring in 55%. Febrile neutropenia occurred in 33% of patients, with Grade 3 or 4 occurring in 32%.

Fatal and serious infectious complications can occur with INQOVI. Pneumonia occurred in 21% of patients, with Grade 3 or 4 occurring in 15%. Sepsis occurred in 14% of patients, with Grade 3 or 4 occurring in 11%. Fatal pneumonia occurred in 1% of patients, fatal sepsis in 1%, and fatal septic shock in 1%.

Obtain complete blood cell counts prior to initiation of INQOVI, prior to each cycle, and as clinically indicated to monitor response and toxicity. Administer growth factors, and antiinfective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose as recommended.

Embryo-Fetal Toxicity: INQOVI can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise patients to use effective contraception during treatment with INQOVI and for 6 months (females) or 3 months (males) after last dose.

ADVERSE REACTIONS

Serious adverse reactions in > 5% of patients included febrile neutropenia (30%), pneumonia (14%), and sepsis (13%). Fatal adverse reactions included sepsis (1%), septic shock (1%), pneumonia (1%), respiratory failure (1%), and one case each of cerebral hemorrhage and sudden death.

The most common adverse reactions ( 20%) were fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The most common Grade 3 or 4 laboratory abnormalities (>50%) were leukocytes decreased, platelet count decreased, neutrophil count decreased, and hemoglobin decreased.

USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with INQOVI and for at least 2 weeks after the last dose.

Renal Impairment: No dosage modification of INQOVI is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLcr] of 30 to 89 mL/min based on Cockcroft-Gault). Due to the potential for increased adverse reactions, monitor patients with moderate renal impairment (CLcr 30 to 59 mL/min) frequently for adverse reactions. INQOVI has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease (ESRD: CLcr <15 mL/min).

Please see the accompanying Full Prescribing Information.

https://www.inqovi.com/pi

To view the FDA Press Release, please see the following link.

https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-myelodysplastic-syndromes-mds-can-be-taken-home

About Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic changes in myeloid, erythroid, and megakaryocytic progenitor cells, and associated with cytopenias affecting one or more of the three lineages. U.S. incidence of MDS is estimated to be 10,000 cases per year, although the condition is thought to be under-diagnosed.7,8 The prevalence has been estimated to be from 60,000 to 170,000 in the U.S.9 MDS may evolve into acute myeloid leukemia (AML) in one-third of patients.10 The prognosis for MDS patients is poor; patients die from complications associated with cytopenias (infections and bleeding) or from transformation to AML.

CMML is a clonal hematopoietic malignancy characterized by accumulation of abnormal monocytes in the bone marrow and in blood. The incidence of CMML in the U.S. is approximately 1,100 new cases per year,11 and CMML may transform into AML in 15% to 30% of patients.12 The hypomethylating agents decitabine and azacitidine are effective treatment modalities and are FDA-approved for the treatment of intermediate and high-risk MDS and CMML. These agents are administered by IV infusion, or by large-volume subcutaneous injections.

About Astex, Taiho, and Otsuka

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in development under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan.

Taiho Oncology, Inc., is a subsidiary of Taiho Pharmaceutical Co., Ltd. and an indirect subsidiary of Otsuka Holdings Co., Ltd. Taiho has established a world-class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents.

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: Otsukapeople creating new products for better health worldwide. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

For more information about Astex Pharmaceuticals, Inc. please visit: https://www.astx.com

For more information about Otsuka Pharmaceutical, please visit: https://www.otsuka.co.jp/en/

For more information about Taiho Pharmaceutical, please visit: https://www.taihooncology.com/

References

CDEC-PM-US-0125

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005938/en/

Continue reading here:
Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical Announce FDA and Health Canada Approval of INQOVI (Decitabine and Cedazuridine)...

On 6th July 2020, the equity market of Australia ended in red, and the benchmark index S&P/ASX200 went down by 43.3 points to 6014.6. The index has gained 3.43% during the last five days. S&P/ASX 200 Materials (Sector) experienced a fall of 162.1 points to 13,339.2. S&P/ASX 200 Utilities (Sector) moved down by 0.12% to 7,787.8. All Ordinaries stood at 6125.9 with a fall of 37.8 points at the end of the same session.

On ASX, the share price of Mesoblast Limited (ASX: MSB) rose by 11.276% to $3.750 per share. The stock of oOh!Media Limited (ASX: OML) inched up by 9.29% and settled the day at $1.000 per share.

Stock Performance (Source: ASX)

S&P/NZX50 ended the trading session at 11,656, reflecting a rise of 0.77%. The share price of TRS Investments Ltd (NZX: TRS) soared by 50.00% to NZ$0.003 per share. New Talisman Gold Mines Limiteds (NZX: NTL) stock moved up by 16.67% to NZ$0.007 per share. On the other hand, the stock of TIL Logistics Group Ltd (NZX: TLL) plunged by 9.09% to NZ$0.700 per share.

Recently, we have covered some crucial information on Krakatoa Resources Limited (ASX: KTA), and the readers can click here to view the article.

Mesoblast Limiteds Stock Rose by 11.276% Due to Initiation of An Expanded Access Protocol in the US.

Mesoblast Limited (ASX: MSB) recently announced the initiation of an expanded access protocol (EAP) in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of the multisystem inflammatory syndrome. For the nine months ended 31st March 2020, the company reported a substantial rise of 113% in revenue to US$31.5 million as compared to US$14.8 million for nine-months ended March 2019.

The manufacturing expenses of the company increased by US$2.5 million to US$15.4 million due to increased expenditure on pre-launch inventory for the potential launch of RYONCIL. The company closed the period with the net cash balance of US$60.1 million.

oOh!Media Limited Ended in Green on 6th July 2020.

oOh!Media Limited (ASX: OML) recently stated that Philippa Kelly has made a change to holdings in the company on 25th June 2020 by acquiring 20,000 fully paid ordinary shares for the consideration of $19,800.00. In response to COVID-19, the company has decreased discretionary spend, negotiated fixed rent expense savings with property partners and slashed its planned capital expenditure to manage its cashflow in the uncertain environment.

Originally posted here:
Understanding the Performance of Markets on 6th July 2020. - Kalkine Media

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Anterior Uveitis Treatment market.

Trusted Business Insights presents an updated and Latest Study on Anterior Uveitis Treatment Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Anterior Uveitis Treatment market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Anterior Uveitis Treatment Market Size & Trends, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Anterior Uveitis Treatment Market

The global anterior uveitis treatment market size was valued at USD 276.78 million in 2018 and is expected to witness a CAGR of 5.4% over the forecast period. Rising incidence of anterior uveitis is majorly driving growth. This disease causes inflammation in anterior part of the uvea of eye. Treatment for such sight threatening diseases primarily includes corticosteroids and immunosuppressive agents. In most of the cases, corticosteroid eye drops are prescribed.Anterior uveitis could arise due to various other diseases as well, which increases its prevalence. National Health Service, U.K., states that corticosteroid prescription depends on the type of uveitis, as it works by disturbing the normal operations of the immune system. In 2017, 12.7% of the worlds population was over 60 years, and it is expected to increase in the coming years. The predisposition to this disease increases with age.

New developments in applications of products and treatment modalities are ongoing, for instance, Humiras approval for treatment of uveitis was a major breakthrough. Hence, factors such as growing geriatric population, rising incidence of the disease, and new product developments are expected to be some of the driving factors. Redness of eyes, blurring of vision, small size of pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness.Increasing incidence of optical infections coupled with rising awareness about various treatments is likely to aid market growth over the forecast period. High expenditure on healthcare, increasing disposable income, and favorable government regulations are some other drivers of the market. Anterior uveitis is one of the common ocular inflammation types that is reported to primary eye care professionals.Patients with anterior uveitis might have altered Intraocular Pressure (IOP). As a result, blood might cover the anterior chamber, affecting visual acuity. Corticosteroid treatment can result in IOP elevation, which is an adverse effect of the drug type. Some of the major complications associated with this type of eye disease are glaucoma, cataract, cystoid macular edema, and band keratopathy.TreatmentType Insights of Anterior Uveitis Treatment Market

There are various types of treatments available: corticosteroids, immunosuppressants, cycloplegic agents, and anti-TNF agents. Corticosteroids dominated the anterior uveitis treatment market in 2018, as they are first line therapies for anterior uveitis. They are used in the form of eye drops as well as systematic therapy. Corticosteroids are also used in sustained release treatment, i.e., in ocular implants. Some of the topical corticosteroid drugs commonly available are prednisolone acetate, betamethasone, dexamethasone sodium phosphate, fluorometholone, loteprednol, and rimexolone.The anti-TNF agents are used as anti-inflammatory agents, while cycloplegic agents are useful in both diagnosis and treatment of the disease. On the other hand, immunosuppressant drugs act by distorting normal functioning of immune system to relive inflammation. These drugs are mainly used in corticosteroid-resistant cases or chronic uveitis cases.Distribution Channel InsightsOn the basis of distribution channel, hospital pharmacies held the largest share in 2018 due to availability of a wide array of options for management of eye inflammation. Moreover, hospitals provide treatment & care to a large number of patients, making hospital pharmacies a leading segment.

Online pharmacies are expected to show lucrative growth during the forecast period, due to the convenience of delivering the medicines at doorstep. The discounted price that the online pharmacies provide is also a factor that drives the market growth. Although hospital pharmacies have shown a trend of price hike in recent years, their location gives an advantage.

Regional Insights of Anterior Uveitis Treatment Market

North America dominated the market in 2018 owing to the rising prevalence of the disease in the U.S. Presence of key players in the region is also leading to high growth of this regional segment. Development of new methods, such as stem cell therapy, for treatment of ocular diseases and approval of drugs like Humira for treatment of this condition are some of the major driving factors.Increase in per capita healthcare expenditure and rising prevalence of the disease are some of the factors driving the market in the European region. Asia Pacific region is expected to show lucrative growth over the forecast period, owing to presence of a large population. In addition, rising prevalence of this condition is also a factor that can be attributed to regional growth. According to NCBI, sarcoidosis, Vogt-Koyanagi-Harada disease, and Behcets disease are very common in the Asia Pacific countries and these conditions can result in anterior uveitis.

Market Share Insights of Anterior Uveitis Treatment Market

Some major players of anterior uveitis treatment market are Novartis AG; Santen Pharmaceutical Co., Ltd; AbbVie Inc.; Eyegate Pharmaceuticals, Inc.; Clearside Biomedical, Inc.; Aldeyra Therapeutics, Inc.; Aciont Inc.; Sirion Therapeutics, Inc.; UCB Biopharma S.P.R.L.; and Lux Biosciences, Inc. Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2018, Clearside Biomedical, Inc. submitted a New Drug Application (NDA) to the U.S. FDA for its XIPERE that is intended for treating uveitic macular edema.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Anterior Uveitis Treatment Market Research ReportThis report forecasts revenue growth at global, regional, & country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2015 2026. For the purpose of this study, this market research report has segmented the anterior uveitis treatment market report on the basis of treatment type, distribution channel, and region:

Treatment Type Outlook (Revenue, USD Million, 2019 2030)

Corticosteroids

Cycloplegic Agents

Anti-TNF Agents

Immunosuppressants

Distribution Channel Outlook (Revenue, USD Million, 2019 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Quick Read Table of Contents of this Report @ Anterior Uveitis Treatment Market Size & Trends, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Anterior Uveitis Treatment Market: Global Industry Valuation 2020| In Depth Analysis, Solution, Industry Influence By 2028 - Cole of Duty

A rating of 77 puts Aldeyra Therapeutics Inc (ALDX) near the top of the Biotechnology industry according to InvestorsObserver. Aldeyra Therapeutics Inc's score of 77 means it scores higher than 77% of stocks in the industry. Aldeyra Therapeutics Inc also received an overall rating of 69, putting it above 69% of all stocks. Biotechnology is ranked 11 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aldeyra Therapeutics Inc (ALDX) stock has gained 12.84% while the S&P 500 is lower by -1.5% as of 11:13 AM on Thursday, Jul 9. ALDX is up $0.56 from the previous closing price of $4.36 on volume of 6,345,048 shares. Over the past year the S&P 500 has gained 4.32% while ALDX is lower by -17.86%. ALDX lost -$2.00 per share the over the last 12 months.

To screen for more stocks like ALDX click here.

Read this article:
Does Aldeyra Therapeutics Inc (ALDX) Stock Beat its Rivals in Biotechnology? - InvestorsObserver

The Global Activated Aspartate Aminotransferase Market 2020 Market Research Report is a professional and in-depth study on the current state of the Activated Aspartate Aminotransferase industry.

The new study made on Activated Aspartate Aminotransferase market includes crucial information on market share, market size, and growth rate for the forecast period 2020 2025. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics.

Major Players Covered in this Report are:SHINO-TEST CORPORATION, BIOSINO Biotechnology Co., Ltd., Beckman Coulter, Inc, Beijing Jin Hao Pharmaceutical Co., Ltd., Abbott Laboratories, Anhui Daqian Biological Engineering Co., Ltd., Hefei Tianyi Biotechnology Institute, Audit Diagnostics, Yangzhou Comay Bio-Medical Electronics Co., Ltd., Human GmbH, HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Guizhou Angel Medical Equipment Co., Ltd.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketgrowthinsight.com/sample/95714

COVID-19 Impact:

The industrial report mentions about the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The Activated Aspartate Aminotransferase report proficiently explains about the resulting factors and concerns of manufacturers. Researchers have also well-explained about how the producers and providers will tackle with the ongoing epidemic and the key strategies to be adopted post pandemic for turning their businesses back to normal.

The updated market research report on Activated Aspartate Aminotransferase market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.

Market Segmentation:

The report is divided into major categories comprising product, distribution channel, application, and end users. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Every segment is studied thoroughly in order to offer a better picture to the buyers and stakeholders to benefit from. Information like highest prevailing product, highly demanded product by the application segment and end users are rightly mentioned in the Activated Aspartate Aminotransferase report.

To get Incredible Discounts on this Premium [emailprotected] https://www.marketgrowthinsight.com/discount/95714

Regional Insights:

The Activated Aspartate Aminotransferase market is segmented as North America, South America, Europe, Asia Pacific, and Middle East and Africa. Researchers have thoroughly studied about the historical market. With extensive research, experts have offered details on the current and the forecast demand made by these regions. The Activated Aspartate Aminotransferase report also includes highlights on the prevailing product demanded by end users and end customers for better understanding of product demand by producers. This will help the producers and the marketing executives to plan their production quantity and plan effective marketing strategies to more buyers. Businesses can hence, increase their product portfolio and expand their global presence. Activated Aspartate Aminotransferase market research report further offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. This will again help the manufacturers to increase their customers and emerge as leaders in the near future.

The report answers important questions that companies may have when operating in the global Activated Aspartate Aminotransferase market. Some of the questions are given below:

If You Have Any Query, Ask Our [emailprotected] https://www.marketgrowthinsight.com/inquiry/95714

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

See the original post:
Activated Aspartate Aminotransferase Market Is Expected To Grow Tremendously By 2025 SHINO-TEST CORPORATION, BIOSINO Biotechnology Co., Ltd - 3rd...

How do you define cytokine storm and sepsis?

Hunter: The last time I had the flu, about 20 years ago, I had a fever, I felt like my bones were being crushed, and I thought I was going to die. That was not because the virus was replicating in my lungs and causing a huge amount of damage; it was that these soluble immune factors everywhere through my bodythese cytokineswere causing this whole-body shutdown and making everything feel terrible. Thats how people think about cytokine storms.

Everyone has cytokines circulating in their bodies; thats a normal part of the immune response. But when that response overshoots where it should be to clear an infection, thats where it becomes pathological and is considered a storm. And it doesnt have to be an infection that triggers it. It could be that something turns on a T cell by mistake, it could be an autoimmune response, or it could be a treatment that boosts the immune response to cure cancer.

Mangalmurti: Sepsis is now defined as an abnormal host response to a pathogen, whether its bacteria, virus, parasite, or fungi. Most people should be able to clear the pathogen and return to a normal state. Sepsis is a dysregulated response where there is not necessarily a return to normal. In sepsis, the response is often characterized by both a hyperinflammatory and an immunosuppressive response happening at the same time.

Hunter: A cytokine storm can be part of that. The question is, At what point does cytokine activation become pathological? Immunologists may talk about cytokine storms, but Im not sure we really understand why they make our muscles ache or cause a fever or respiratory distress or heart failure. Thats one of the things were trying to explain. Why does it feel like this? How does it amplify? Why do some people make an appropriate response to control infection and live while some overshoot and die?

A through-line of this work seems to be that the immune response isnt always either completely protective or completely harmful, but it can be somewhere in between?

Hunter: Yes, its all about balance. Of course, we know that an immune response can be protective, but there are also immune-mediated diseases. Everyone knows someone with an immune-mediated condition like arthritis, lupus, diabetes, and inflammatory bowel disease.

How have the two of you been working together?

Hunter: When Nilam and I first met I quickly realized my interests coincided with hers. I do basic immunology studying mice, while Nilams science is informed by her time in the ICU. Ive enjoyed getting her perspective on how disease works and the model infectious system that my laboratory uses. When Immunity asked us to write a primer for people who didnt really know what a cytokine storm was, we took that opportunity and ran with it.

Mangalmurti: A pandemic is never a good thing, but it has been a learning opportunity for all of us and a chance to bring together bench-based scientists with physicians and physician-scientists. We have a huge number of sepsis researchers on campus that dont necessary think theyre studying sepsis or dont contextualize their work that way.

A group of physicians and immunologists, including Chris and myself, started a joint sepsis working group so we could bring together scientists from many walks of life, so anyone from clinical epidemiology to fundamental basic scientists. The first meeting we had there were so many ideas flying back and forth about sepsis and pathogens and host response. It was exciting to see people from PSOM, the Childrens Hospital of Philadelphia, and Penn Vet so engaged.

Now with the pandemic, a focus on understanding the host response to infection is amplified and relevant to questions like why some people with COVID have no symptoms while others get hit really hard.

How is what were seeing with COVID-19 confirming or changing what we understand about cytokine storms and how to address them in patients?

Mangalmurti: Part of why I wanted to do this primer was to sort through this amazing amount of information about COVID that has been pouring in from Twitter, bioRxiv, and medRxiv and other places and try to make sense of it.

There was an opinion piece in the Lancet early on in the pandemic that everyone latched onto that suggested that specific therapies to tamp down cytokine storms were going to be beneficial for COVID. It was early in the pandemic, and this idea seemed to make sense. But we dont have rigorous evidence to back that up and, as we have learned more, we realized that it is not so simple.

In sepsis, multiple therapies to block cytokine have been tried before, and there hasnt been any survival benefit. In fact, there has been some increased mortality, maybe because the drugs are not striking the right balance of immune response versus immune suppression or are not being used at the right time point in the infection.

One thing that was very clear to us after the first week of seeing COVID-19 patients was that most who came into the ICU with organ failure clearly had a condition that seemed to predispose them to vascular injury: obesity, diabetes, high blood pressure, age, a history of vascular disease, or clots. And that was striking because its not something we usually see in most other forms of sepsis, or other forms of acute respiratory distress syndrome.

That got us thinking about innate immunity in the vascular compartment and whether this virus had a penchant for the vasculature. Maybe theres a way to use what we know about this relationship with the vasculature to design and use more targeted anticytokine therapies.

Of course, when patients are doing poorly, clinicians are often desperate for a treatment. I understand that; we just need to remember to proceed with caution when were treating with drugs outside of a controlled trial.

Hunter: From my perspective its exciting to think about targeted therapies that are already available, like antibodies to cytokines that are already used in the clinic; maybe they could be repurposed and used in this setting. But we really need large clinical trials to assess whether our excitement about some of these approaches is meaningful and valid. Perhaps one consequence of the pandemic is that more people will be thinking about how to more effectively use cytokine therapies or cytokine neutralizing approaches, not just in COVID-19 but in sepsis in general. Sepsis is a disease where the advances in immunology have not yet had the same impact that they have in other conditions, such as cancer and autoimmunity.

Can the idea of a cytokine storm help explain the spectrum of responses weve seen to the coronavirus, from asymptomatic patients to those with severe disease?

Mangalmurti: There are certainly anecdotes from people who get this disease that they are home, theyre having fevers every night, they dont feel well. These people are having a cytokine storm, but it resolves, and they dont end up on a ventilator in the ICU. Maybe those patients dont have the predisposing factors that we talked about. It could also be that they have less of a viral load.

Hunter: No one is studying the asymptomatic patients. One question is, How asymptomatic are they really? Maybe they had a small fever one day; maybe that was their cytokine shower.Also, as Nilam mentioned, in every other system the amount of the virus you are exposed to matters, so Im not sure why it wouldnt matter here, too.

You wrote this primer hoping to reach an audience of immunologists. What do you hope they start doing or doing more of?

Hunter: We, the basic immunologists, need to be thinking more about the physiology of what were doing. Often, well look at immune cells in isolation. We need to look at their effects on the vascular system, the impact on lung function, the impact on heart function. In general, we need to realize that it is really important to understand a whole disease process, to look at the system more broadly.

Your work seems to underscore the value of collaboration across fields.

Hunter: Absolutely. Nilam has worked on sepsis and has been seeing sepsis patients for a long time. Shes dealing with really sick patients who have a lot going on. Basic scientists tend to want to simplify and reduce things. And youve got to meet somewhere in the middle, I think, for complex diseases. Penn is a really good place to do that, at PSOM, CHOP, and Penn Vet.

Mangalmurti: Im usually talking with clinicians about ARDS and sepsis, and now to partner with immunologists who are taking a deep dive into the cytokines, into the pathobiology of these things and looking more at the host-pathogen interface, its a really nice intersection. As awful as the pandemic has been, I hope some of our trainees will be intrigued by all these unanswered questions and want to learn more about disease processes.

Read more from the original source:
Navigating cytokine storms | Penn Today - Penn: Office of University Communications

In the past 10 years, science has provided the recipe for a tasty new Florida-grown strawberry sold in local produce aisles, put drones into the hands of 4-Hers and revealed where to catch snook off Cedar Key. It may even have improved your marriage.

I dont blame you if you werent aware of many ways the University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) touches your lives. Ive led UF/IFAS for a decade, and Im still learning about the vast scope of what we do.

Our berry breeders creating new varieties of food and our Department of Family, Youth and Community Sciences offering couples classes are two examples of how UF/IFAS aims to improve the lives of 22 million Floridians. In addition to serving those who produce food for a living, we serve everyday citizens like you.

Our fisheries experts track the movement of species popular among anglers in the Gulf. Our Extension agents have expanded 4-H to include drones, 3-D printing, robotics and other science-themed learning.

Youve had a hand in this. Support for public science ensures the continued state investment in discovery and innovation. Of course, the need for that discovery grows as the state does. There are nearly 3 million more people in Florida than when I arrived in 2010.

My parting request as I retire this month is to please continue supporting public science. Your participation and feedback help us pursue the science most relevant to your lives.

For example, fishing boat captains guide our scientists to the best places to tag fish so we can monitor the health of fisheries. Citizens report to our entomologists what ants they find in their yards, revealing a geographic range and a variety of species we cant see from the lab.

Gainesville has been a great place to be a scientist because of public support and amenities that make this a great place to live and work.

My dogs receive the best possible medical treatment because of the people at the UF College of Veterinary Medicine, which UF/IFAS and UF Health run jointly. My mornings are so much better because of Sweetwater Organic Coffee.

Having access to miles of bike path along Archer Road has allowed me to go on pre-dawn rides that maintained my health and perhaps extended my career. Being able to walk to the Limerock Road Neighborhood Grill made it convenient for me to hold frank after-hours discussions with friends and colleagues on how to keep agriculture thriving.

Gainesville and Florida have given UF/IFAS a great deal, and weve done our best to reciprocate. In the past decade weve built a state-of-the-art bee lab that trains hundreds of beekeepers from Alachua County and across the state to maintain hives of pollinators for crops and for backyard plants.

We rebuilt the Roland T. Stern Learning Center in the Austin Cary Forest off Waldo Road as a hub for fire science aimed at preventing the worst effects of wildfires. Its such a beautiful building and setting that its become a popular wedding spot.

In Cedar Key we built the Nature Coast Biological Station to focus on the science needed to protect the most pristine and natural shoreline in Florida. Not only that, but it has become a true community partner that organizes beach cleanups and other civic events, not just scientific ones

Long before the pandemic prompted farmers whod lost restaurant and hotel customers to open their farms for direct sales to the public, we connected producer and consumer. We brought Gainesville residents on tours of farms throughout the county.

UF/IFAS has driven UFs rise to top 10. After all, by at least one ranking, UF/IFAS has the best entomology and nematology department in the world. The College of Agricultural and Life Sciences is consistently ranked in the top five ag schools, seemingly regardless of what metrics are used. That boost in stature will attract the best and brightest students and employees to become members of your community in Gainesville.

Please welcome them, including my successor and longtime friend, Dr. Scott Angle. Then let them know what you need help with so they can work on the science of solutions. You can expect great things from UF/IFAS.

Jack Payne is retiring this month as UFs senior vice president for agriculture and natural resources and leader of IFAS.

Continued here:
Jack Payne: UF/IFAS aims to improve lives of Floridians - The Florida Times-Union

A 90-minute virtual side event hosted by World Horse Welfare and The Donkey Sanctuary at this years United Nations High Level Political Forum (HLPF) on the Sustainable Development Goals (SDGs) has been recorded and made available for public viewing.

Working Animals: Climate Change and Public Health Issues in achieving the SDGs was supported by the UN Food and Agriculture Organisation (FAO) and the Permanent Mission of the Republic of Senegal to the UN, represented by guest of honour, ambassador Abdoulaye Barro.

The live webinar was hosted by Roly Owers, CEO of World Horse Welfare. He welcomed presentations from a variety of experts from around the world and introduced the event, run via Zoom because of the pandemic, by noting The policies relating to the health and welfare of working animals really is relevant to climate, the health of people, the health of animals and the health of the environment.

The SDGs, set by the UN in 2015 and due to run until 2030, are designed to move the world towards a sustainable future for all.

Ambassador Barro from the Permanent Mission of the Republic of Senegal to the UN, spoke of the importance of working animals to the health and economy of his country with almost a million working equids.

Almost all farmers use equids, and 57% of Senegal is arable land and family farms. The income produced from a working horse can feed a family of six. They are multipurpose animals and also respectful of fragile environments, much more so than mechanisation.

Dr Rebecca Doyle from the University of Melbourne and International Livestock Research Institute showed that existing welfare challenges for working animals and livestock will continue and will be exacerbated by climate change. She went on to present examples of where working animals are contributing to achieving SDGs. Daniela Battaglia, of the Food and Agriculture Organization of the UN, introduced to the event the concept and importance of a One Health approach: Recognizing the connection between humans, animals, plants and their shared environments in an integrated effort to reduce disease and pest threats and ensure safe food supply.

Talking about the trade in donkey skins, Ian Cawsey, Director of Advocacy & Campaigns at The Donkey Sanctuary, pointed out that These skins are transported across the world with little sanitation. Not only are communities deprived of the working donkeys they need, but it also poses a biosecurity risk which we should all be concerned about.

Dr Aileen Pypers, a behavioural vet and consultant running Pets at Play throughout South Africa, highlighted that there are anecdotal ideas abounding around working animals that dont necessarily have research to back them up but that they should be supported and explored.

BonnieWyper, from Thinking Animals United, summarised the importance of working animals in achieving SDGs: Without acknowledging thatanimalsimpact on every single SDG, Im not sure SDGs can actually succeed.

A Q&A session followed the presentations,with stakeholders invited to submit their questions. These focusedon how awareness of therole healthy, working animals can play in attaining the SDGs, while mitigating the spread of disease during the global health crisis can be raised, with research, veterinarian training and childrens education emerging as the most valuable routes.

See original here:
Improving lives and livelihoods: UN webinar on working equines - Horsetalk

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the companys principal contract development and manufacturing partners, today announced that they have extended their collaboration initiated in April 2018 for a period of five years through June 2025.

With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies in the upcoming years, including OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott Aldrich syndrome (WAS), as well as for additional pipeline programs including OTL-203 for mucopolysaccharidosis type I (MPS-I). MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

We are looking forward to continuing to build and expand upon our partnership with MolMed, who have supported the progression of many of our programs since their earliest clinical development stages, said Frank Thomas, president and chief operating officer of Orchard. Their expertise in gene therapy manufacturing, coupled with their deep knowledge of our programs, will be invaluable as our therapies for MLD and WAS approach anticipated approval and commercialization in Europe and across the globe.

Luca Alberici, MolMed's chief business officer, added, "We are pleased to have strengthened our collaboration with Orchard to support them in their mission of bringing potentially transformative therapies to those suffering from severe rare diseases. After being Orchards exclusive manufacturer for Strimvelis, we are looking forward to supporting their manufacturing needs for additional programs both in clinical trials and in potential commercial applications following the anticipated approval of OTL-200 for MLD in Europe later this year.

OTL-200 for MLD is currently under review by the EMA with a decision expected later this year.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

About MolMedMolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of novel cell and gene therapies. MolMed, established in 1996, has been listed since March 2008 on the Italian Stock Exchange managed by Borsa Italiana, and has its registered office in Milan, at the Biotechnology Department of Ospedale San Raffaele and an operating site at Bresso, at the OpenZone campus.

Availability of Other Information About OrchardInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for or marketing approval of its product candidates, and Orchards expectations concerning its partnership with MolMed. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the risk of delays in Orchards ability to commercialize its product candidates, if approved; and the risk that Orchard may not receive the expected benefits from its collaboration with MolMed or that Orchard or MolMed will not fully perform under the terms of their collaboration agreement. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter ended March 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC) on May 7, 2020, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Orchard Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

MolMed Contacts

Investor Relations & Communications DepartmentMolMed S.p.A.+39 02 21277.205investor.relations@molmed.com

Tommasina CazzatoPress OfficeCommunity Group+39 345 7357751tommasina.cazzato@communitygroup.it

Read more here:
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration - BioSpace